v3.26.3
Equity Transactions
3 Months Ended
Sep. 30, 2026
Equity Transactions  
Equity Transactions

Note 8 - Equity Transactions

On July 1, 2026 the Company and Dr. Anil Diwan entered into an extension of his employment agreement for a period of one year from July 1, 2026 through June 30, 2027 under the same general terms and conditions. The Company granted Dr. Anil Diwan an award of 10,204 shares of the Company’s Series A preferred stock. The shares shall be vested in quarterly installments of 2,551 shares on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027 and are subject to forfeiture. The Company recognized non-cash compensation expense related to the issuance of the Series A preferred stock of $9,921 for the three months ended September 30, 2026. The balance of $29,763 will be recognized as the remaining 7,653 shares vest and service is rendered for the remaining nine months ended June 30, 2027.

At The Market Sales Agreement

On July 17, 2026, the Company entered into an At The Market Issuance Sales Agreement (the “Sales Agreement”) with D. Boral Capital LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agent, shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), in an “at the market” offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”).

On July 17, 2026, the Company filed a prospectus supplement with the U.S. Securities and Exchange Commission (the “Commission”) in connection with the Sales Agreement (the “Prospectus Supplement”) under its existing shelf Registration Statement on Form S-3 (File No. 333-296550) (the “Registration Statement”) initially filed with the Commission on June 5, 2026 and declared effective on June 15, 2026, and the base prospectus included therein.

Sales of Common Stock, if any, may be made by any method permitted by law deemed to be an “at the market” offering, including sales made directly on the NYSE American or on any other existing trading market for the Common Stock. The Sales Agent may also sell shares of Common Stock by any other method permitted by law, including in privately negotiated transactions, with the Company’s prior written consent.

The Company will instruct the Sales Agent as to the parameters of each sale of shares of Common Stock under the Sales Agreement by delivery of a placement notice. The Sales Agent will use its best efforts consistent with its normal trading and sales practices and applicable law to sell shares of Common Stock under the Sales Agreement on the terms and subject to the conditions set forth therein. The Company has agreed to pay the Sales Agent a commission equal to 2.0% of the aggregate gross proceeds from each sale of shares of Common Stock sold through the Sales Agent under the Sales Agreement. The shares of Common Stock that may be offered and sold pursuant to the Sales Agreement (the “Placement Shares”) will be issued and sold pursuant to the Registration Statement and the Prospectus Supplement. The offer and sale of the Placement Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the issuance and sale of all of the Placement Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by the Company or the Sales Agent pursuant to the terms thereof. Pursuant to the Registered Direct Offering Sales Agreement entered into on July 24, 2026, the Company has agreed not to issue any shares of the Company’s common stock through the ATM until after September 26, 2026. There were no sales through the ATM during the three months ended September 30, 2026.

Registered Direct Offering

On July 24, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investor in a registered direct offering: (i) 2,416,339 shares of common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $1.53 per share, (ii) pre-funded warrants to purchase up to 100,000 shares of Common Stock, at an offering price of $1.52999 per pre-funded warrant (the “Pre-Funded Warrants”), and (iii) accompanying common warrants to purchase up to 2,516,339 shares of Common Stock (the “ Common Warrants”). Each Pre-Funded Warrant will be exercisable for one share of Common Stock at an exercise price of $0.00001 per share, will be immediately exercisable upon issuance, and may be exercised at any time until exercised in full. Each Common Warrant will be exercisable for one share of Common Stock at an exercise price of $1.75 per share, will be exercisable six months from the date of issuance, may be exercised at any time until exercised in full, and will expire five and one-half years from the date of issuance. The Offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-296550) that was filed with the Securities and Exchange Commission (the “SEC”) on June 5, 2026 and declared effective by the SEC on June 15, 2026 and the prospectus supplement filed with the SEC on July 27, 2026.

Pursuant to the July Securities Purchase Agreement, the Company has agreed for a period of 60 days after the Closing Date (as defined below) not to issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents, or file any registration statement or any amendment or supplement thereto, except for the filing of the Resale Registration Statement (as defined below).

In addition, the Company agreed that within thirty (30) days following the Closing Date, the Company shall prepare and file a registration statement (the “Resale Registration Statement”) with the Securities and Exchange Commission covering the resale of the shares of Common Stock issuable upon exercise of the Warrants, and shall use commercially reasonable efforts to cause such registration statement to be declared effective as promptly as practicable and to keep such registration statement continuously effective until the earlier of (i) the date all Common Warrant Shares covered hereby have been sold or (ii) the date all Common Warrant Shares may be sold without restriction pursuant to Rule 144 under the Securities Act of 1933, as amended. The Company shall bear all expenses associated with the filing and maintenance of the Resale Registration Statement, other than underwriting discounts, commissions, and legal fees of the holders.

The Company allocated the aggregate proceeds between the common stock and warrants based on their respective relative fair values on the issuance date. The fair value of the warrants was estimated using the Black-Scholes option pricing model. Of the aggregate proceeds, approximately $1,248,000 was allocated to the warrants. The Company incurred approximately $427,500 of direct offering costs, consisting primarily of placement agency fees and legal fees. These costs were allocated between the common stock and warrants using the same relative fair value percentages applied to the allocation of the gross proceeds. Approximately $138,595 of the offering costs was allocated to the warrants and recorded as a reduction of additional paid-in capital attributable to warrants. Accordingly, the net amount recorded in additional paid-in capital attributable to warrants was approximately $1,109,575.

The Offering closed on July 27, 2026 (the “Closing Date”). The Pre-Funded Warrants were exercised at closing. The company issued 2,516,339 of the Company’s $0.00001 par value common shares. The Company generated gross proceeds from the Offering of approximately $3,850,000 and net proceeds of approximately $3,422,000 after deduction of the placement agent’s fee, offering expenses and other expenses payable by the Company. D. Boral Capital LLC acted as the exclusive placement agent for the Company in connection with the July Offering.

For the three months ended September 30, 2026, the Company’s Board of Directors authorized the issuance of 387 fully vested shares of its Series A preferred stock for employee compensation. The Company recorded expense of $1,528 for the three months ended September 30, 2026 related to this issuance.

There is currently no market for the shares of Series A preferred stock and they can only be converted into shares of common stock upon a change of control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A preferred stock granted to various employees and others on the date of grant. The conversion of the shares is triggered by a change of control. The fair value of the Series A Convertible preferred stock at each issuance was estimated based upon the price of the Company’s common stock after an application for a reasonable discount for lack of marketability.

The Scientific Advisory Board was granted in August 2026 fully vested warrants to purchase 286 shares of common stock with an exercise price of $1.65 per share expiring in August 2030. The fair value of the warrants was $139 for the three months ended September 30, 2026 and was recorded as consulting expense.

The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following assumptions:

​

​

​

​

​

Expected life (years)

  ​ ​ ​

4

 

​

​

​

​

Expected volatility

​

44.06

%

​

​

​

​

Expected annual rate of quarterly dividends

​

0.00

%

​

​

​

​

Risk-free rate(s)

​

4.30

%

​

For the three months ended September 30, 2026, the Company’s Board of Directors authorized the issuance of 19,384 fully vested shares of the Company’s common stock with a restrictive legend for consulting and legal services. The Company recorded an expense of $27,000 for the three months ended September 30, 2026, which is reflective of the fair value of the common stock on the dates of issuance.

For the three months ended September 30, 2026, the Company’s Board of Directors authorized the issuance of 8,004 fully vested shares of its common stock with a restrictive legend for director services. The Company recorded an expense of $11,250 for the three months ended September 30, 2026, which is reflective of the fair value of the common stock on the dates of issuance.